Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 2/20 | 0.47 |
| ▸ | PYGM | P11217 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | TYMP | P19971 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12240330 | 0.88 | PYGM (0.56) | TK2PYGM | |
| SCHEMBL1699665 | 0.88 | PYGM (0.56) | TK2PYGM | |
| SCHEMBL1699647 | 0.88 | PYGM (0.56) | TK2PYGM | |
| SCHEMBL12240327 | 0.88 | PYGM (0.56) | TK2PYGM | |
| SCHEMBL2614692 | 0.88 | PYGM (0.56) | TK2PYGM | |
| SCHEMBL2614693 | 0.88 | PYGM (0.56) | TK2PYGM | |
| SCHEMBL18750458 | 0.83 | TK2 (0.56) | TK2ALDH1A1LMNAALBPOLB | |
| SCHEMBL774129 | 0.83 | TK2 (0.63) | TK2PYGMALDH1A1LMNAALB | |
| SCHEMBL26872396 | 0.82 | SLC28A1 (0.56) | — | |
| SCHEMBL15691447 | 0.80 | TK2 (0.50) | TK2PYGMALDH1A1LMNAALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10456473-B2 | Lipid compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-10-29 | — | — | US | disclosed |
| US-20180104342-A1 | LIPID COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104342-A1 | LIPID COMPOSITIONS | SGMS1, LIPA, SGMS2 | TK2 3371/4885PYGM 4203/4885ALDH1A1 1867/4885 |
| US-10456473-B2 | Lipid compositions | SGMS1, LIPA, SGMS2 | TK2 3371/4885PYGM 4203/4885ALDH1A1 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.